Keryx Biopharmaceuticals, Inc. to Present at the 35th Annual Goldman Sachs Global Healthcare Conference

Keryx Logo

NEW YORK, June 5, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Greg Madison, the Company's Chief Operating Officer, will present a corporate overview at the 35th Annual Goldman Sachs Global Healthcare Conference to be held from June 10-12, 2014 at the Terranea Resort in Rancho Palos Verdes, CA.

Mr. Madison's presentation will take place on Thursday, June 12, at 10:00 a.m. Pacific Time (1:00 p.m. ET).

A live audio webcast of Mr. Madison's presentation will be accessible within the Investor Relations section of the Company's website at An archived version of this webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients suffering from renal disease. In the United States, ZerenexTM (ferric citrate) is currently under review by the Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in dialysis-dependent chronic kidney disease (CKD) patients. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd.

CONTACT: Amy Sullivan Vice President - Corporate Development and Public Affairs Keryx Biopharmaceuticals, Inc. Tel: 617.466.3447 E-mail:

Source:Keryx Biopharmaceuticals, Inc.